BOULDER, Colo.–(BUSINESS WIRE)–Enveda, a biotechnology company using AI to translate nature into new medicines, announced today that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for its first asset targeting atopic dermatitis and other inflammatory conditions. The company also announced it has entered this candidate, named ENV-294, into a Phase I clinical trial, with the first patient dosed at the end of October. The novel oral first-in
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
